Reduction of thiamine and thiamine-dependent enzyme activity resulted in tau phosphorylation, Aβ accumulation, and oxidative stress exacerbation, leading to increased interest in benfotiamine (BFT) as a potential PSP therapy (Tapias et al., 2018). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.